AIM AIM ImmunoTech Inc.

Price Chart

Executive Summary

AIM ImmunoTech entered into a securities purchase agreement and placement agency agreement for a combined registered direct offering and private placement, selling 7,519,351 shares of common stock at $0.325 per share (a ~21% discount to the prior close of $0.41) to institutional investors, along with Series I warrants to purchase up to 15,038,702 additional shares at $0.325 per share (subject to shareholder approval). The offering raised approximately $2.44M in gross proceeds, with net proceeds of ~$2.25M for working capital. This follows a 424B5 filed just one day prior for the same offering, and a prior 424B5 on May 19 suspending an ATM facility. The massive potential dilution (up to ~22.6M new shares vs. a ~$2M market cap) and deeply discounted pricing are strongly bearish for existing common shareholders.

Key Financial Metrics

Actionable Insight

Key Facts

• Company sold 7,519,351 shares at $0.325/share, a ~21% discount to the $0.41 closing price on May 18, 2026.
• Gross proceeds of ~$2.44M; net proceeds of ~$2.25M after placement agent fees and expenses.
• Issued Series I warrants to purchase up to 15,038,702 shares at $0.325/share, exercisable for 5 years after shareholder approval.
• Placement agent (Ladenburg Thalmann) received 451,162 warrants at $0.40625/share (125% of offering price).
• Total potential dilution: 7,519,351 shares + 15,038,702 warrant shares + 451,162 agent warrants = ~23M new shares, dwarfing the current market cap of ~$2M.
• Shareholder meeting required by July 21, 2026 to approve warrant exercise; warrants are non-exercisable until approval.
• This offering follows a 424B5 filed May 19 suspending an ATM facility, and a 424B5 filed May 21 for the same offering.
• Company has a $2M market cap and is a pre-revenue clinical-stage biotech with ongoing financial distress.

Financial Impact

Gross proceeds of ~$2.44M at a 21% discount; potential dilution of up to ~23M shares vs. ~$2M market cap, representing massive overhang.

Risk Factors

• Massive dilution from 7.5M shares and up to 15.5M additional warrant shares could overwhelm the micro-cap float.
• Shareholder approval for warrants may fail, but the company has committed to repeated votes every 90 days until approval.
• Company has a history of repeated dilutive financings; cash runway remains uncertain.
• Pre-revenue clinical-stage biotech with no approved products and ongoing losses.

Market Snapshot

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status